Abstract: A document acquisition unit (15c) collects documents, a feature amount calculation unit (15d) calculates feature amounts of words included in the collected documents, a relevance calculation unit (15f) calculates relevances between the documents and words included in operation logs in a window operated by a user, using the calculated feature amounts of the words included in the documents, and a presentation unit (15g) presents, to the user, a predetermined number of the documents in an order of descending relevance, as related documents. In this manner, it is possible to present documents related to a user's operation to the user.

Abstract: A document acquisition unit (15c) collects documents, a feature amount calculation unit (15d) calculates feature amounts of words included in the collected documents, a relevance calculation unit (15f) calculates relevances between the documents and words included in operation logs in a window operated by a user, using the calculated feature amounts of the words included in the documents, and a presentation unit (15g) presents, to the user, a predetermined number of the documents in an order of descending relevance, as related documents. In this manner, it is possible to present documents related to a user's operation to the user.

Abstract: A display control apparatus including a first icon storage section storing a first icon; a second icon storage section storing a second icon; a first correspondence information storage section storing a combination of mobile terminal identification information and application identification information, in association with the second icon; a mobile terminal identification information receiving section receiving mobile terminal identification information from a mobile terminal; an application identification information receiving section receiving application identification information from the mobile terminal; and a display control section displaying the second icon in a display section if the combination of mobile terminal identification information received by the mobile terminal identification information receiving section and application identification information received by the application identification information receiving section is stored in the first correspondence information storage section, and

Abstract: A display control apparatus including a first icon storage section storing a first icon; a second icon storage section storing a second icon; a first correspondence information storage section storing a combination of mobile terminal identification information and application identification information, in association with the second icon; a mobile terminal identification information receiving section receiving mobile terminal identification information from a mobile terminal; an application identification information receiving section receiving application identification information from the mobile terminal; and a display control section displaying the second icon in a display section if the combination of mobile terminal identification information received by the mobile terminal identification information receiving section and application identification information received by the application identification information receiving section is stored in the first correspondence information storage section, and

Abstract: With an aim to provide a novel factor inducing proliferation of neural stem cells and differentiation of these cells into nerve cells, a pharmaceutical composition comprising 1) CRBN, 2) a nucleic acid encoding CRBN, or 3) a stem cell or a neural progenitor cell in which CRBN is expressed, a method including administering the pharmaceutical composition to a non-human animal and inducing proliferation of neural stem cells or neural progenitor cells of the non-human animal and differentiation of these cells into nerve cells, and a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex, using CRBN, are provided.

Abstract: With an aim to provide means for developing a compound devoid of teratogenicity but retaining beneficial actions, a screening method for a non-teratogenic substance comprising bringing a test substance into contact with cereblon or a fragment of cereblon, evaluating the bindability of the test substance with cereblon or the fragment of cereblon, and selecting a test substance that does not bind to cereblon or the fragment of cereblon or a test substance exhibiting lower bindability with cereblon or the fragment of cereblon than does thalidomide is provided.

Abstract: With an aim to provide a novel factor inducing proliferation of neural stem cells and differentiation of these cells into nerve cells, a pharmaceutical composition comprising 1) CRBN, 2) a nucleic acid encoding CRBN, or 3) a stem cell or a neural progenitor cell in which CRBN is expressed, a method including administering the pharmaceutical composition to a non-human animal and inducing proliferation of neural stem cells or neural progenitor cells of the non-human animal and differentiation of these cells into nerve cells, and a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex, using CRBN, are provided.

Abstract: With an aim to provide means for developing a compound devoid of teratogenicity but retaining beneficial actions, a screening method for a non-teratogenic substance comprising bringing a test substance into contact with cereblon or a fragment of cereblon, evaluating the bindability of the test substance with cereblon or the fragment of cereblon, and selecting a test substance that does not bind to cereblon or the fragment of cereblon or a test substance exhibiting lower bindability with cereblon or the fragment of cereblon than does thalidomide is provided.

Abstract: With an aim to provide a novel factor inducing proliferation of neural stem cells and differentiation of these cells into nerve cells, a pharmaceutical composition comprising 1) CRBN, 2) a nucleic acid encoding CRBN, or 3) a stem cell or a neural progenitor cell in which CRBN is expressed, a method including administering the pharmaceutical composition to a non-human animal and inducing proliferation of neural stem cells or neural progenitor cells of the non-human animal and differentiation of these cells into nerve cells, and a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex, using CRBN, are provided.